miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNAs (miRNAs) play critical roles in cancer development and progression.
• Osteosarcoma (OS) is a primary bone malignancy with complex molecular underpinnings.
• Dysregulation of specific miRNAs is increasingly recognized in OS pathogenesis.

Purpose of the Study:

• To investigate the role of miR-16 in osteosarcoma.
• To identify the molecular targets and pathways regulated by miR-16 in OS.
• To evaluate the therapeutic potential of miR-16 in OS.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) to assess miR-16 expression in OS cell lines and tissues.
• In vitro cell proliferation assays and in vivo tumor xenograft models in nude mice to evaluate the functional role of miR-16.
• Western blotting and luciferase reporter assays to confirm IGF1R as a direct target of miR-16.
• Analysis of signaling pathways, including Raf1-MEK1/2-ERK1/2.
• Correlation analysis between miR-16 and IGF1R expression in clinical osteosarcoma specimens.

Main Results:

• miR-16 was significantly downregulated in osteosarcoma cell lines and clinical tissues.
• Overexpression of miR-16 suppressed osteosarcoma cell proliferation and inhibited tumor growth in vivo.
• Insulin-like growth factor 1 receptor (IGF1R) was identified as a direct target of miR-16.
• miR-16 overexpression led to the inhibition of the Raf1-MEK1/2-ERK1/2 signaling pathway.
• A negative correlation was observed between miR-16 expression and IGF1R levels in clinical osteosarcoma specimens.

Conclusions:

• miR-16 functions as a tumor suppressor in osteosarcoma.
• Targeting IGF1R by miR-16 is a key mechanism underlying its tumor-suppressive function.
• miR-16 modulates the Raf1-MEK1/2-ERK1/2 pathway, contributing to its anti-proliferative effects in OS.
• These findings highlight miR-16 as a potential therapeutic target for osteosarcoma treatment.